Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of HSK39297 in primary IgA nephropathy
ChiCTR2400089578Phase 2Not yet recruiting
- Sponsor
- Peking University First Hospital
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ciprocopan in IgA nephropathy (IgAN) and primary glomerulonephritis (4 arms), sponsored by Peking University First Hospital. Primary endpoint: 24-hour urinary protein creatinine ratio. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
ciprocopan
03
Conditions
IgA nephropathy (IgAN)primary glomerulonephritis
Beyond the preview
Go deeper on ChiCTR2400089578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089578.